Track topics on Twitter Track topics that are important to you
Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that it will pres...
Innovative immuno-therapy company welcomes a recognized leader in life sciences and therapeutics Triumvira Immunologics, a privately-held biopharmaceutical company deve...
Experienced biotech executive takes helm of promising T-Cell Therapy company as it moves several programs toward clinical testing Triumvira Immunologics Canada Inc. and Triumv...
Dr. Lammers brings more than 27 years of experience in product and clinical development spanning the pharmaceutical and biotechnology industries.
Douglas Russell joins LHS as Senior Vice President & General Manager LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advanc...
Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hami...
Signature Immunologics produces anti-hapten IgGs for High Performance Immunocytochemistry (HPI), targeting key small molecules in cell physiology, including fast neurotransmitter amino acids and pivot...
We have published hundreds of Triumvira Immunologics news stories on BioPortfolio along with dozens of Triumvira Immunologics Clinical Trials and PubMed Articles about Triumvira Immunologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Triumvira Immunologics Companies in our database. You can also find out about relevant Triumvira Immunologics Drugs and Medications on this site too.